Search Results - "Koreth, John"

Translational and clinical advances in acute graft-versus-host disease by Gooptu, Mahasweta, Koreth, John

“…Acute graft-versus-host disease (aGvHD) is induced by immunocompetent alloreactive T lymphocytes in the donor graft responding to polymorphic and…”
Get full text

Mechanistic approaches for the prevention and treatment of chronic GVHD by Cutler, Corey S., Koreth, John, Ritz, Jerome

“…Clinical outcomes for patients undergoing allogeneic hematopoietic stem cell transplantation continue to improve, but chronic graft-versus-host disease (GVHD)…”
Get full text

Molecular assessment and the current limits of post-transplant prognostication for chronic myelomonocytic leukemia by Gibson, Christopher J, Koreth, John

Get full text

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial by Stadtmauer, Edward A, Pasquini, Marcelo C, Blackwell, Beth, Hari, Parameswaran, Bashey, Asad, Devine, Steven, Efebera, Yvonne, Ganguly, Siddharta, Gasparetto, Cristina, Geller, Nancy, Horowitz, Mary M, Koreth, John, Knust, Kristin, Landau, Heather, Brunstein, Claudio, McCarthy, Philip, Nelson, Courtney, Qazilbash, Muzaffar H, Shah, Nina, Vesole, David H, Vij, Ravi, Vogl, Dan T, Giralt, Sergio, Somlo, George, Krishnan, Amrita

“…Single-cycle melphalan 200 mg/m and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved…”
Get full text

A post-transplant optimized transplant-specific risk score in myelodysplastic syndromes by Gooptu, Mahasweta, Koreth, John

Get full text

Better acute graft- versus -host disease outcomes for allogeneic transplant recipients in the modern era: a tacrolimus effect? by Gooptu, Mahasweta, Koreth, John

Get full text

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease by Koreth, John, Kim, Haesook T., Jones, Kyle T., Lange, Paulina B., Reynolds, Carol G., Chammas, Marie J., Dusenbury, Katherine, Whangbo, Jennifer, Nikiforow, Sarah, Alyea, Edwin P., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Chen, Yi-Bin, Avigan, David, Blazar, Bruce R., Antin, Joseph H., Ritz, Jerome, Soiffer, Robert J.

“…Chronic graft-versus-host disease (cGVHD) is associated with inadequate reconstitution of tolerogenic CD4+CD25+FOXP3+ regulatory T cells (Tregs). Previous…”
Get full text

A disease risk index for patients undergoing allogeneic stem cell transplantation by Armand, Philippe, Gibson, Christopher J., Cutler, Corey, Ho, Vincent T., Koreth, John, Alyea, Edwin P., Ritz, Jerome, Sorror, Mohamed L., Lee, Stephanie J., Deeg, H. Joachim, Storer, Barry E., Appelbaum, Frederick R., Antin, Joseph H., Soiffer, Robert J., Kim, Haesook T.

“…The outcome of allogeneic HSCT varies considerably by the disease and remission status at the time of transplantation. Any retrospective or prospective HSCT…”
Get full text

Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant by Ballen, Karen K., Koreth, John, Chen, Yi-Bin, Dey, Bimalangshu R., Spitzer, Thomas R.

“…Only 30% of patients who require an allogeneic hematopoietic cell transplant will have an HLA-matched sibling donor. A search for an unrelated donor will be…”
Get full text

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation by Cutler, Corey, Multani, Pratik, Robbins, David, Kim, Haesook T., Le, Thuy, Hoggatt, Jonathan, Pelus, Louis M., Desponts, Caroline, Chen, Yi-Bin, Rezner, Betsy, Armand, Philippe, Koreth, John, Glotzbecker, Brett, Ho, Vincent T., Alyea, Edwin, Isom, Marlisa, Kao, Grace, Armant, Myriam, Silberstein, Leslie, Hu, Peirong, Soiffer, Robert J., Scadden, David T., Ritz, Jerome, Goessling, Wolfram, North, Trista E., Mendlein, John, Ballen, Karen, Zon, Leonard I., Antin, Joseph H., Shoemaker, Daniel D.

“…Umbilical cord blood (UCB) is a valuable source of hematopoietic stem cells (HSCs) for use in allogeneic transplantation. Key advantages of UCB are rapid…”
Get full text

Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism by Flynn, Ryan, Paz, Katelyn, Du, Jing, Reichenbach, Dawn K., Taylor, Patricia A., Panoskaltsis-Mortari, Angela, Vulic, Ante, Luznik, Leo, MacDonald, Kelli K.P., Hill, Geoffrey R., Nyuydzefe, Melanie S., Weiss, Jonathan M., Chen, Wei, Trzeciak, Alissa, Serody, Jon S., Aguilar, Ethan G., Murphy, William J., Maillard, Ivan, Munn, David, Koreth, John, Cutler, Corey S., Antin, Joseph H., Ritz, Jerome, Waksal, Samuel D., Zanin-Zhorov, Alexandra, Blazar, Bruce R.

“…Chronic graft-versus-host disease (cGVHD) remains a major complication following allogeneic bone marrow transplantation (BMT). The discovery of novel…”
Get full text

Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis by KORETH, John, PIDALA, Joseph, FENAUX, Pierre, JADERSTEN, Martin, HELLSTROM-LINDBERG, Eva, GALE, Robert Peter, BEACH, C. L, LEE, Stephanie J, HOROWITZ, Mary M, GREENBERG, Peter L, TALLMAN, Martin S, DIPERSIO, John F, PEREZ, Waleska S, BUNJES, Donald, WEISDORF, Daniel J, CUTLER, Corey, DEEG, H. Joachim, GARCIA-MANERO, Guillermo, MALCOVATI, Luca, CAZZOLA, Mario, PARK, Sophie, ITZYKSON, Raphael, ADES, Lionel

“…Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders that are more common in patients aged ≥ 60 years and are incurable with conventional…”
Get full text

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation by Armand, Philippe, Kim, Haesook T., Cutler, Corey S., Ho, Vincent T., Koreth, John, Alyea, Edwin P., Soiffer, Robert J., Antin, Joseph H.

“…Iron overload could be a significant contributor to treatment-related mortality (TRM) for patients with hematologic malignancies undergoing hematopoietic stem…”
Get full text

Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation by Cutler, Corey, Kim, Haesook T., Sun, Lixian, Sese, Doreen, Glotzbecker, Brett, Armand, Philippe, Koreth, John, Ho, Vincent, Alyea, Edwin, Ballen, Karen, Ritz, Jerome, Soiffer, Robert J., Milford, Edgar, Antin, Joseph H.

“…Using a uniform detection method for donor-specific anti-HLA antibodies (DSAs), we sought to determine the effect of preformed DSAs on outcomes in double…”
Get full text

A case of Epstein Barr virus-related post-transplant lymphoproliferative disorder after haploidentical allogeneic stem cell transplantation using post-transplantation cyclophosphamide by Hickey, Cindy Lynn, Romee, Rizwan, Nikiforow, Sarah, Dorfman, David, Mazzeo, Michael, Koreth, John

Get full text

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation by Penter, Livius, Zhang, Yi, Savell, Alexandra, Huang, Teddy, Cieri, Nicoletta, Thrash, Emily M., Kim-Schulze, Seunghee, Jhaveri, Aashna, Fu, Jingxin, Ranasinghe, Srinika, Li, Shuqiang, Zhang, Wandi, Hathaway, Emma S., Nazzaro, Matthew, Kim, Haesook T., Chen, Helen, Thurin, Magdalena, Rodig, Scott J., Severgnini, Mariano, Cibulskis, Carrie, Gabriel, Stacey, Livak, Kenneth J., Cutler, Corey, Antin, Joseph H., Nikiforow, Sarah, Koreth, John, Ho, Vincent T., Armand, Philippe, Ritz, Jerome, Streicher, Howard, Neuberg, Donna, Hodi, F. Stephen, Gnjatic, Sacha, Soiffer, Robert J., Liu, X. Shirley, Davids, Matthew S., Bachireddy, Pavan, Wu, Catherine J.

“…Relapsed myeloid disease after allogeneic stem cell transplantation (HSCT) remains largely incurable. We previously demonstrated the potent activity of immune…”
Get full text

Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease by Sarantopoulos, Stefanie, Stevenson, Kristen E., Kim, Haesook T., Cutler, Corey S., Bhuiya, Nazmim S., Schowalter, Michael, Ho, Vincent T., Alyea, Edwin P., Koreth, John, Blazar, Bruce R., Soiffer, Robert J., Antin, Joseph H., Ritz, Jerome

“…Chronic graft-versus-host disease (cGVHD) causes significant morbidity and mortality in patients otherwise cured of malignancy after hematopoietic stem cell…”
Get full text

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation by Kim, Haesook T, Baker, Peter O, Parry, Erin, Davids, Matthew, Alyea, Edwin P, Ho, Vincent T, Cutler, Corey, Koreth, John, Gooptu, Mahasweta, Romee, Rizwan, Nikiforow, Sarah, Antin, Joseph H, Ritz, Jerome, Soiffer, Robert J, Wu, Catherine J, Brown, Jennifer R

Get full text

Bortezomib-Based Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Transplantation by KORETH, John, STEVENSON, Kristen E, SOIFFER, Robert J, RITZ, Jerome, ALYEA III, Edwin P, KIM, Haesook T, MCDONOUGH, Sean M, BINDRA, Bhavjot, ARMAND, Philippe, HO, Vincent T, CUTLER, Corey, BLAZAR, Bruce R, ANTIN, Joseph H

“…HLA-mismatched unrelated donor (MMUD) hematopoietic stem-cell transplantation (HSCT) is associated with increased graft-versus-host disease (GVHD) and impaired…”
Get full text

Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial by Cutler, Corey, Kim, Haesook T., Bindra, Bhavjot, Sarantopoulos, Stefanie, Ho, Vincent T., Chen, Yi-Bin, Rosenblatt, Jacalyn, McDonough, Sean, Watanaboonyongcharoen, Phandee, Armand, Philippe, Koreth, John, Glotzbecker, Brett, Alyea, Edwin, Blazar, Bruce R., Soiffer, Robert J., Ritz, Jerome, Antin, Joseph H.

“…B cells are implicated in the pathophysiology of chronic graft-vs-host disease (GVHD), and phase 2 trials suggest that B cell depletion can treat established…”
Get full text